
    
      Multi-center, double-masked, randomized, placebo-controlled study comprising 5 visits over
      the course of approximately 9 weeks. Qualified subjects are randomized 1:1 to receive either
      SkQ1 Ophthalmic Solution, or Placebo (vehicle of SkQ1 Ophthalmic Solution).

      The Primary Endpoints are:

      Change from Baseline (Visit 2) to Visit 5 of Ocular Discomfort;

      Change from Baseline (Visit 2) to Visit 5 of conjunctival fluorescein staining (sum of
      temporal and nasal regions)
    
  